Evidence map›Paper›PMID 30718952›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease

Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Alan Kaplan, Kenneth R Chapman, Syed M Anees, Irvin Mayers, Driss Rochdi, Michel Djandji, David Préfontaine, Andrew McIvor

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02202616 (Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02202616 phase4completednot on this map

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2014 to 2017Enrolled401ConditionsChronic Obstructive Pulmonary DiseaseArmsGlycopyrronium /Indacaterol maleate
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Time to Prescribe Dual instead of Mono.Tuberculosis and respiratory diseases · 2021
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Alan KaplanFamily Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada, for4kids@gmail.com.
Kenneth R ChapmanDivision of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Syed M AneesSchulich School of Medicine & Dentistry - Western University, University of Windsor, ON, Canada.
Irvin MayersDivision of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Driss RochdiNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Michel DjandjiNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
David PréfontaineNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Andrew McIvorDepartment of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada.
Novartis (Canada) · CAUniversity of Toronto · CAWestern University · CAMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn contrast to randomized controlled trials (RCTs), changes in maintenance pharmacotherapy in clinical practice occur without a washout period. The Prospective cohort study for the real-life effectiveness evaluation of glycOpyrronium With indacatERol combination in the management of COPD in Canada (POWER) study evaluated the real-life effectiveness of indacaterol/glycopyrronium (IND/GLY) following a direct switch from a long-acting muscarinic antagonist (LAMA, tiotropium) or long-acting β

methodsPOWER was a single-cohort, prospective, multicenter, interventional study in which patients with moderate-to-severe COPD, who remained symptomatic on their current treatment of once-daily (od) tiotropium 18 µg or twice-daily (bid) SFC (any dose), were switched to treatment with open-label IND/GLY 110/50 µg od for 16 weeks. Effectiveness end points were change from baseline in trough FEV

resultsTrough FEV

conclusionIn clinical practice settings, a direct switch from previous treatment with either tiotropium or SFC to IND/GLY was safe and provided superior clinically significant improvements in lung function and patient-related outcomes in patients with moderate-to-severe COPD. CLINICAL

trial registrationNCT02202616.

Indexed as

Drug SubstitutionAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsCanadaDrug CombinationsDyspneaFemaleFluticasone-Salmeterol Drug CombinationForced Expiratory VolumeGlucocorticoidsGlycopyrrolateHealth StatusHumansIndansLungAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsFluticasone-Salmeterol Drug CombinationGlucocorticoidsGlycopyrrolateindacaterol-glycopyrronium combinationIndansMuscarinic AntagonistsQuinolonesTiotropium BromideCOPD assessment testdyspneaFEV1indacaterol/glycopyrroniumlung functionTDI

Identifiers

PMID30718952
PMCPMC6343749
OpenAlexW2909669915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.